- A retrospective analysis suggests that fumaric acid esters (FAEs) are safe and beneficial for long-term systemic treatment of patients with moderate-to-severe psoriasis.
Why this matters
- This study provides needed data on long-term maintenance treatments for patients with moderate-to-severe psoriasis.
- Median time to a 50% response rate (cumulative static Physician’s Global Assessment [PGA] score of “light” and ≥2-point reduction in baseline PGA) was 1 year for each cohort (FAE monotherapy, concomitant phototherapy, and concomitant methotrexate; P=.70 for differences among cohorts).
- Median time to 50% response rate for cumulative Psoriasis Area and Severity Index (PASI) 75 was 3 years for the FAE monotherapy cohort, 6.7 years for the concomitant phototherapy cohort, and 8.1 years in the concomitant methotrexate cohort (P=.001).
- 49.0% of patients experienced adverse events:
- 3.5% reported serious adverse events;
- 12.9% experienced adverse events leading to treatment discontinuation.
- 859 patients with moderate-to-severe psoriasis (626 received FAE monotherapy; 123 received FAEs with concomitant phototherapy; 110 received FAEs with methotrexate) were analyzed for response rates for up to 32.5 years of follow-up.
- Funding: Biogen GmbH.
- Retrospective study from a single center.